Séverine Vermeire

ORCID: 0000-0001-9942-3019 · 1 paper in corpus

2024

Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.

Inflammatory bowel diseases ·doi:10.1093/ibd/izae024

BackgroundMirikizumab, a p19-directed interleukin-23 monoclonal antibody, is efficacious in inducing clinical remission at week 12 (W12) and maintaining clinical remission at W52 in patients with moderately to severely active ulcerative col…